Biomarin Pharmaceutical Inc (BMRN) — Cash Flow-to-Debt Ratio
Biomarin Pharmaceutical Inc (BMRN) has a Cash Flow-to-Debt Ratio of 0.09x as of March 2026, meaning its operating cash flow of $220.65 Million could theoretically repay 0% of its total liabilities ($2.38 Billion) in one year. Explore BMRN long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Biomarin Pharmaceutical Inc Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Biomarin Pharmaceutical Inc across 28 annual periods. Also explore total assets of Biomarin Pharmaceutical Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Biomarin Pharmaceutical Inc (1998–2025)
Year-by-year debt coverage analysis for Biomarin Pharmaceutical Inc. For market capitalisation and broader financial context, see Biomarin Pharmaceutical Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.55x | $827.99 Million | $1.51 Billion | ▲ +27.7% |
| 2024 | 0.43x | $572.84 Million | $1.33 Billion | ▲ +410.8% |
| 2023 | 0.08x | $159.26 Million | $1.89 Billion | ▼ -15.1% |
| 2022 | 0.10x | $175.90 Million | $1.77 Billion | ▼ -43.5% |
| 2021 | 0.18x | $304.54 Million | $1.73 Billion | ▲ +258.7% |
| 2020 | 0.05x | $85.36 Million | $1.74 Billion | ▲ +59.2% |
| 2019 | 0.03x | $48.26 Million | $1.57 Billion | ▲ +122.3% |
| 2018 | 0.01x | $20.21 Million | $1.46 Billion | ▲ +388.5% |
| 2017 | 0.00x | $-8.76 Million | $1.82 Billion | ▲ +97.4% |
| 2016 | -0.18x | $-227.84 Million | $1.26 Billion | ▼ -8.6% |
| 2015 | -0.17x | $-221.69 Million | $1.33 Billion | ▼ -118.4% |
| 2014 | -0.08x | $-73.54 Million | $962.56 Million | ▼ -15.7% |
| 2013 | -0.07x | $-59.63 Million | $903.02 Million | ▼ -307.2% |
| 2012 | 0.03x | $17.61 Million | $552.58 Million | ▼ -9.5% |
| 2011 | 0.04x | $18.75 Million | $532.66 Million | ▲ +2.4% |
| 2010 | 0.03x | $18.75 Million | $545.37 Million | ▼ -76.7% |
| 2009 | 0.15x | $87.73 Million | $594.98 Million | ▲ +1112.5% |
| 2008 | -0.01x | $-9.18 Million | $630.02 Million | ▲ +73.5% |
| 2007 | -0.05x | $-34.49 Million | $627.55 Million | ▲ +62.1% |
| 2006 | -0.14x | $-50.09 Million | $345.63 Million | ▲ +36.9% |
| 2005 | -0.23x | $-62.68 Million | $272.76 Million | ▼ -6.2% |
| 2004 | -0.22x | $-65.14 Million | $300.94 Million | ▲ +59.9% |
| 2003 | -0.54x | $-74.80 Million | $138.49 Million | ▲ +87.8% |
| 2002 | -4.44x | $-53.59 Million | $12.07 Million | ▼ -136.0% |
| 2001 | -1.88x | $-23.07 Million | $12.26 Million | ▼ -1.2% |
| 2000 | -1.86x | $-12.90 Million | $6.94 Million | ▲ +25.7% |
| 1999 | -2.50x | $-12.94 Million | $5.17 Million | ▲ +34.8% |
| 1998 | -3.84x | $-8.10 Million | $2.11 Million | — |